1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Erasca, Inc.
  6. News
  7. Summary
    ERAS   US29479A1088

ERASCA, INC.

(ERAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Erasca : Guggenheim Starts Erasca at Buy With $25 Price Target

08/10/2021 | 06:51am EDT


ę MT Newswires 2021
All news about ERASCA, INC.
05/12Erasca Narrows Q1 Loss, Misses Street Estimates
MT
05/12ERASCA, INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
05/12Earnings Flash (ERAS) ERASCA Reports Q1 Loss $-0.31
MT
05/12Erasca Reports First Quarter 2022 Financial Results and Business Updates
GL
05/12Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
AQ
04/27ERASCA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/27Erasca Appoints Jean Liu to its Board of Directors
AQ
04/27Erasca Appoints Jean Liu to its Board of Directors
CI
04/12Erasca Says Data Support Clinical Development of Certain Programs
MT
More news
Analyst Recommendations on ERASCA, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -165 M - -
Net cash 2022 275 M - -
P/E ratio 2022 -4,45x
Yield 2022 -
Capitalization 707 M 707 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 123
Free-Float 79,8%
Chart ERASCA, INC.
Duration : Period :
Erasca, Inc. Technical Analysis Chart | ERAS | US29479A1088 | MarketScreener
Technical analysis trends ERASCA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 5,80 $
Average target price 22,40 $
Spread / Average Target 286%
EPS Revisions
Managers and Directors
Jonathan E. Lim Chairman & Chief Executive Officer
David M. Chacko Chief Business Officer
Michael D. Varney Chairman-Research & Development
Wei Lin Chief Medical Officer
Les Brail VP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ERASCA, INC.-62.77%707
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153